Intranasal Submucosal Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

NCT01314274 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

15

Enrollment

OTHER

Sponsor class

Conditions

HHT
Morbus Osler
Epistaxis

Interventions

DRUG: Bevacizumab
DRUG: NaCl

Sponsor

Medical University of Vienna